Insights from the Liraglutide Clinical Development Program—the Liraglutide Effect and Action in Diabetes (LEAD) Studies

References

• . World Health Organization (WHO). Diabetes fact sheet. http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed April 3, 2009
   Google Scholar
• . Cowie CC, Rust KF, Ford ES, . Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32(2):287–294
   PubMed Web of Science ®Google Scholar
• . Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008;31(1):102–104
   PubMed Web of Science ®Google Scholar
• . Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81–86
   PubMed Web of Science ®Google Scholar
• . U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249–1258
   PubMed Web of Science ®Google Scholar
• . Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187–218
   PubMed Web of Science ®Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28(5):995–1000
   PubMed Web of Science ®Google Scholar
• . Riedel AA, Heien H, Wogen J, Plauschinat CA. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care. 2007;13(8):457–463
   PubMedGoogle Scholar
• . Kahn SE, Haffner SM, Heise MA, ; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Brown JB, Nichols JA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27(7):1535–1540
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Complications of Diabetes in the United States. http://www.diabetes.org/diabetes-statistics/complications.jsp. Accessed April 16, 2009
   Google Scholar
• . Vilsbøll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004;47(3): 357–366
   PubMed Web of Science ®Google Scholar
• . Stoffers DA, Kieffer TJ, Hussain MA, . Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49(5):741–748
   PubMed Web of Science ®Google Scholar
• . Farilla L, Bulotta A, Hirshberg B, . Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149–5158
   PubMed Web of Science ®Google Scholar
• . Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002;18(6):430–441
   PubMedGoogle Scholar
• . Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag. 2009;5:199–211
   PubMedGoogle Scholar
• . Vilsbøll T, Zdravkovic M, Le-Thi T, . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30(6): 1608–1610
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Shaw J, Brandle M, . The once-daily human glucagon-like peptide-1 analog liraglutide reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline. Presented at: American Diabetes Association's 68th Scientific Sessions; June 6–10, 2008; San Francisco, CA
   Google Scholar
• . Nauck M, Frid A, Hermansen K, . Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, . A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet. In press
   Google Scholar
• . Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2008
   Google Scholar
• . Marre M, Shaw J, Brändle M, ; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R, ; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Zinman B, Gerich J, Buse JB, . Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) [published online ahead of print March 16, 2009]. Diabetes Care.
   Google Scholar
• . Russell-Jones D, Vaag A, Schmitz O, . Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes. Presented at: American Diabetes Association's 68th Scientific Sessions; June 6–10, 2008; San Francisco, CA
   Google Scholar
• . Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD™) trial. Expert Rev Endocrinol Metab. 2009;4(2):119–129
   PubMedGoogle Scholar
• . Moretto TJ, Milton DR, Ridge TD, . Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–1460
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Zinman B, Hoogwerf BJ, Durán García S, . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–485
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5): 1083–1091
   PubMed Web of Science ®Google Scholar
• . McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med. 2009; 121(1): 46–58
   PubMed Web of Science ®Google Scholar
• . Nauck MA. Unraveling the science of incretin biology. Am J Med. In press
   Google Scholar
• . Knudsen LB, Nielsen PF, Huusfeldt PO, . Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664–1669
   PubMed Web of Science ®Google Scholar
• . Göke R, Fehmann HC, Linn T, . Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650–19655
   PubMed Web of Science ®Google Scholar
• . Clinical Trials Registry. The Effect of Insulin Detemir in Combination with Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects with Type 2 Diabetes. http://clinicaltrial.gov/ct2/show/NCT00856986?term=liraglutide&rank=1. Accessed April 16, 2009
   Google Scholar
• . Clinical Trials Registry. The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus. http://clinicaltrial.gov/ct2/show/NCT00700817?term=liraglutide&rank=9. Accessed April 16, 2009
   Google Scholar
• . Noel R, Braun D, Patterson R, Bloomgren G. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. Presented at: 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 17–20, 2008; Copenhagen, Denmark
   Google Scholar
• . Wolf AM, Conaway MR, Crowther JQ, . Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care. 2004;27(7):1570–1576
   PubMed Web of Science ®Google Scholar
• . Colagiuri S, Frid A, Zdravkovic M, Le-Thi T, Vaag A. The once-daily human GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Presented at: American Diabetes Association's 68th Scientific Sessions; June 6–10, 2008; San Francisco, CA
   Google Scholar
• . Genuth S, Eastman R, Kahn R ; American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2003;(26 suppl 1):S28–S32
   Google Scholar